Gabelli & Co Investment Advisers’s Bio-Rad Laboratories Class A BIO Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$240K	–	266
2023 Q1	$240K	Hold	500	–	–	0.05%	140
2022 Q4	$210K	Hold	500	–	–	0.04%	185
2022 Q3	$209K	Hold	500	–	–	0.03%	314
2022 Q2	$248K	Buy	+500	New	+$260K	0.03%	306
2020 Q4	–	Sell	-400	Closed	-$206K	–	330
2020 Q3	$206K	Sell	400 -100	-20%	-$50.6K	0.04%	179
2020 Q2	$226K	Buy	+500	New	+$221K	0.05%	145

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Gabelli & Co Investment Advisers's BIO Position: Q2 2023 in Review

Gabelli & Co Investment Advisers sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 500 shares — an estimated $240K sold.

Gabelli & Co Investment Advisers first reported a position in BIO in Q2 2020 and held it in 6 quarters. The position peaked at $248K in Q2 2022. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Gabelli & Co Investment Advisers reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 500 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $240K.
Gabelli & Co Investment Advisers first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 6 quarters.
Gabelli & Co Investment Advisers's Bio-Rad Laboratories Class A position peaked at $248K in Q2 2022.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.